AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01096329
Drug: Intrinsa® Patch and Testosterone Spray 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
Trial: NCT03073850
Drug: Standard dose oral anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban of 60mg
Trial: NCT01756898
Drug: 5 mg ASB17061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
Trial: NCT01756898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo taken once daily for 28 consecutive days.
Trial: NCT01756898
Drug: 10 mg ASB17061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
Trial: NCT01756898
Drug: 20 mg ASB17061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
Trial: NCT02652884
Drug: saline 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of intramuscular placebo
Trial: NCT00235079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00820560
Drug: INCB007839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB007839 100 or 200 mg/dose as IR capsules
Trial: NCT01391507
Drug: COR-1
RxNorm normalized name: Corticosteroid-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravenous injection for 6 months
Trial: NCT01391507
Drug: Standard therapy for heart failure
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
Trial: NCT00840879
Drug: Meloxicam 15 mg Tablets
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose fed
Trial: NCT00840879
Drug: Mobic® 15 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose fed
Trial: NCT03875547
Drug: Refixia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
Trial: NCT03031821
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration
Trial: NCT04594252
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablets.
Trial: NCT03197818
Drug: CHF 5993 100/6/12.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
Trial: NCT00130936
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02070042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (olive oil) twice a day
Trial: NCT01562548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active ingredient
Trial: NCT02392286
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
Trial: NCT00229021
Drug: doripenum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00834717
Drug: Kytril® 1 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1 mg, single dose fasting
Trial: NCT04183335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Trial: NCT04183335
Drug: Moisturizers
RxNorm normalized name: SPF 8 Lip Moisturizers KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:~Route of administration: Topical
Trial: NCT04183335
Drug: Topical calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:~Route of administration: Topical
Trial: NCT00352989
Drug: Smecta (Diosmectite), duration of treatment - 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01783535
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01783535
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
Trial: NCT01750294
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00665925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, either once a day, or twice a day
Trial: NCT03665194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04338698
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
Trial: NCT01756547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03413020
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic for H. pylori eradication
Trial: NCT01171456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
Trial: NCT01788007
Drug: Zyclara® (imiquimod) Topical Cream 3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Trial: NCT01957059
Drug: Regimen Selection Phase Group 2
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg
Trial: NCT01450982
Drug: JNJ-38518168 / MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
Trial: NCT01243736
Drug: Combination Prep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope.
Trial: NCT01957059
Drug: Regimen Selection Phase Group 3
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg
Trial: NCT01957059
Drug: Treatment Phase Group 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
Trial: NCT01957059
Drug: Regimen Selection Phase Group 1 (COMPLETED)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of BMN053 have been administered as subcutaneous injections.
Trial: NCT01957059
Drug: Dosing Extension
RxNorm normalized name: EXTENSION TUBES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
Trial: NCT03873805
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03220958
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml normal saline
Trial: NCT01463098
Drug: E2006 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 1.0 mg capsule.
Trial: NCT01463098
Drug: E2006 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 2.5 mg capsule.
Trial: NCT01463098
Drug: E2006 5.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 5.0 mg (2 capsules of 2.5 mg each).
Trial: NCT01463098
Drug: E2006 10.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 10.0 mg capsule.
Trial: NCT01463098
Drug: E2006 25.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
Trial: NCT01463098
Drug: E2006 50.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 50.0 mg capsule.
Trial: NCT01463098
Drug: E2006 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 100 mg (2 capsules of 50 mg each).
Trial: NCT01463098
Drug: E2006 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006 200 mg (4 capsules of 50 mg each).
Trial: NCT01463098
Drug: E2006 Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006-matched placebo capsule.
Trial: NCT01705574
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC tablet administered orally with food once daily
Trial: NCT00495651
Drug: Antiretroviral medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
Trial: NCT00495651
Drug: Antiretroviral medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early ART initiation on the day of inclusion, before reaching the current WHO criteria
Trial: NCT01705574
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet administered orally with food once daily
Trial: NCT01705574
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally with food once daily
Trial: NCT01705574
Drug: E/C/F/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally with food once daily
Trial: NCT01705574
Drug: ATV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally with food once daily
Trial: NCT01705574
Drug: RTV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally with food once daily
Trial: NCT01705574
Drug: FTC/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally with food once daily
Trial: NCT01705574
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally with food once daily
Trial: NCT01405456
Drug: Eplerenone and lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 50mg by mouth daily as well as lifestyle counseling
Trial: NCT00731172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous daiky injection through week 12
Trial: NCT00859521
Drug: Keppra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Tablet
Trial: NCT02914262
Drug: AKB-4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of AKB-4924
Trial: NCT01934088
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006023
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00834132
Drug: Azithromycin 600 mg Tablet
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 600mg, single-dose fed
Trial: NCT00834132
Drug: Zithromax® 600 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 600mg, single-dose fed
Trial: NCT03558854
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Trial: NCT03558854
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Trial: NCT02840097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is provided to participants if randomized to this treatment arm.
Trial: NCT00164775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tab nocte for first 2 weeks then 2 tabs for 10 weeks
Trial: NCT03754309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00666627
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once monthly
Trial: NCT00430508
Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
Trial: NCT00430508
Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Trial: NCT00430508
Drug: olmesartan medoxomil/hydrochlorothiazide tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Trial: NCT00430508
Drug: olmesartan medoxomil/hydrochlorothiazide tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
Trial: NCT01637233
Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI+PI
Trial: NCT04673162
Drug: Methylprednisolone, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration
Trial: NCT01147939
Drug: Investigator's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
Trial: NCT00797823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9%
Trial: NCT00810979
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were dosed with the statin prescribed specifically by their prescribing physician.
Trial: NCT00003211
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01882491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT02702648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules for oral administration
Trial: NCT00278681
Drug: Zinc and ORS
RxNorm normalized name: zinc gluconate Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water.
Trial: NCT02380677
Drug: CRLX301
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02877615
Drug: S 44819 150 mg twice a day
RxNorm normalized name: Horseman's Dream Fung-A-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sachet of S 44819 150 mg and one sachet of placebo twice a day
Trial: NCT02877615
Drug: S 44819 300 mg twice a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sachets of S 44819 150 mg twice a day
Trial: NCT02877615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sachets of placebo twice a day
Trial: NCT00999908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Trial: NCT00309569
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600mg/m2
Trial: NCT00309569
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40mg/m2
Trial: NCT00309569
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 600mg/m2
Trial: NCT01945450
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
Trial: NCT01945450
Drug: Gentamycin
RxNorm normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01945450
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01937182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2-2 tablets per day with no intrinsic drug activity
Trial: NCT01681550
Drug: Incretin-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04600895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01747174
Drug: IC Adenosine
RxNorm normalized name: Cyclic adenosine monophosphate
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
Trial: NCT03591276
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
Trial: NCT03986294
Drug: S1 + Nal-IRI
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
Trial: NCT03986294
Drug: Nal-IRI+Leucovorin+5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
Trial: NCT03431987
Drug: One day with a dose of active THC cannabis paired with alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
Trial: NCT00288080
Drug: Oral antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
Trial: NCT00288080
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
Trial: NCT00608322
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide, 40 parts per million, for six hours.
Trial: NCT02933658
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03906123
Drug: NBP
RxNorm normalized name: Tri-N-Butyl Phosphate (TNBP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBP soft capsules
Trial: NCT03906123
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft capsules manufactured to mimic NBP
Trial: NCT02913924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00606281
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 0mg(4tablets)/day